Brief: Gracell Biotechnologies Presents Clinical Data For Fastcar-T Gc012f
10/12/2022 23:22
Dec 10 (Reuters) - Gracell Biotechnologies Inc GRCL.O :
* GRACELL BIOTECHNOLOGIES PRESENTS CLINICAL DATA FOR
FASTCAR-T
GC012F FOR HIGH RISK, NEWLY DIAGNOSED MULTIPLE MYELOMA
DEMONSTRATING 100% OVERALL RESPONSE RATE
* AS OF OCT. 14, 2022, AMONG 16 EVALUABLE PATIENTS WITH
MEDIAN
FOLLOW-UP TIME OF EIGHT MONTHS ORR WAS 100%
* GRACELL BIOTECHNOLOGIES - NO IMMUNE EFFECTOR
CELL-ASSOCIATED
NEUROTOXICITY SYNDROME (ICANS) OR OTHER NEUROTOXICITY OF ANY
GRADE HAD BEEN OBSERVED
Source text for Eikon: ID:nPn5JBPCVa
Further company coverage: GRCL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gracell Biotechnologies
See all newsBrief: Gracell Biotechnologies Announces Shareholders’ Approval Of Merger Agreement
Brief: Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
Newscasts - UK Day Ahead: European shares start last week of 2023 on strong footing
Live Markets: European futures rise after holiday break
Press Digest: British Business - Dec 27